Purchase Order 75F40119P10423
Award Date 7/30/19
Potential Completion Date 7/29/22
Potential Value $170K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20903, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $91,396 firm fixed-price purchase order issued by the Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (De), for the ratification of Phoenix Quantum licenses in fiscal year 2017. Certara is a technology-enabled drug development and drug safety consultancy that specializes in biosimulation and has received multiple federal contracts from the Department of Health and Human Services, including the FDA, National Institutes of Health, and Centers for...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Certara USA Inc., doing business as Tripos (De), to provide annual licenses and maintenance for the Phoenix Quantum software suite. The $151,470.39 award does not have a set-aside designation. Certara, a technology-enabled drug development and drug safety consultancy, has previously received federal contracts from the FDA, NIH, and CDC to provide pharmacokinetic modeling and...
- This is a $845,852.26 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Certara USA Inc. for the licensing of the company's CDER CERTARA PHOENIX software products. The award is not associated with a set-aside program and is intended to provide the FDA's Office of Clinical Pharmacology with necessary software tools, including Phoenix WinNonlin, NLME, IVIVC, Connect, and Trial Simulator, to support the review of Investigational New Drug (IND), New Drug...
- The Food and Drug Administration (FDA) awarded a $65,451.84 firm fixed-price purchase order to Certara USA Inc. (doing business as Tripos (De)) for Phoenix Quantum licenses and support services. The contract was awarded on July 11, 2019, with an ultimate completion date of July 11, 2024, and was performed in Princeton, New Jersey. This contract reflects the FDA's ongoing reliance on Certara's pharmacokinetic and pharmacodynamic modeling software to support regulatory review activities and drug...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Certara USA Inc., a leading provider of biosimulation software and consulting services. The contract, valued at $16,441.10, is for the procurement of software licenses for Certara's proprietary modeling and simulation tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers to conduct...
- This firm-fixed price purchase order contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Certara UK LIMITED, doing business as Certara, a for-profit limited liability company. The $164,400 contract provides annual licenses and maintenance support for Certara's SIMCYP physiologically-based pharmacokinetic modeling software. The software is used by the FDA's Office of Clinical Pharmacology to review submissions from pharmaceutical sponsors,...
- The Department of Health and Human Services' National Institutes of Health has awarded a firm fixed-price purchase order to Certara USA Inc., a leading global drug development and drug safety consultancy, for the provision of Phoenix WinNonlin software licenses. The $12,266.00 contract will enable federal scientists and reviewers to conduct clinical pharmacology, pharmacometric, and regulatory review analyses on data submitted by industry sponsors. Certara has received numerous prime contracts...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Pharsight Corporation, a subsidiary of Certara USA Inc. The contract, valued at $153,470.00, is for the provision of the "PHOENIX QUANTUM SOFTWARE BUNDLE" and is a total small business set-aside. The contract has a completion date of July 21, 2017. Certara USA Inc. is a leading global technology-enabled drug development and drug safety consultancy, specializing in biosimulation...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Purchase Order contract to Certara USA Inc. for the procurement of the Phoenix WinNonlin software. The contract has a potential value of $19,950.00 and a completion date of May 31, 2025. This contract supports federal scientists and reviewers in conducting clinical pharmacology, pharmacometric, and regulatory review analyses on...
- This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Certara USA Inc. for the annual provision of the Phoenix WinNonlin software. The $17,556.00 contract has a period of performance ending on July 22, 2025 and is not designated as a set-aside award. Certara USA Inc. is a leading global technology-enabled drug development and drug safety...